Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

HIV-Related Malignancies Increasing, Physicians Tell Panel

August 1, 1995
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 8
Volume 4
Issue 8

BETHESDA, Md--The three-member President's Cancer Panel heard evidence from a number of speakers that HIV-related malignancies are increasing at a significant rate.

BETHESDA, Md--The three-member President's Cancer Panel heardevidence from a number of speakers that HIV-related malignanciesare increasing at a significant rate.

Judith Karp, MD, NCI assistant director for applied science, speakingfor Edward Sondik, acting director of NCI, told the panel thatthe putative Kaposi's sarcoma virus, a newly discovered herpesvirus,may be an "agent provocateur" in both Kaposi's sarcomaand HIV-related lymphoma.

She said that scientists face major challenges in initiating clinicalinvestigations of HIV-related malignancies: "There are alimited number of patients, it is sometimes difficult to recruitpatients into investigative clinical trials, and we face challengesin clinical agent development. We need to define meaningful endpointsfor novel agents such as angiogenesis inhibitors and cytokines."

Ellen Feigal, MD, senior investigator in the NCI Cancer TherapyEvaluation Program (CTEP), said that despite logistical, financial,and other problems, it is important to study HIV-related cancers.

She noted that use of antiretroviral therapy and treatments foropportunistic infection have improved survival of HIV-infectedpatients, and thus cancer incidence will continue to rise.

She cited a need to study the relationship between a well-definedonset of impaired immunity and cancer pathogenesis, as well asthe relationship between a virus and cancer development. In addition,she said, recent advances in knowledge about the pathogenesisof HIV related cancers provide an opportunity to test new therapeuticapproaches.

Dr. Feigal urged collaboration among NIH, the pharmaceutical industry,FDA, and independent investigators to develop effective treatmentsand interventions as quickly as possible. She encouraged studiesof therapeutic approaches that take into account the treatmentof the underlying HIV disease as well as the cancer.

Edward L. Trimble, MD, head of the surgery section, CTEP, andJoel Palefsky, MD, Department of Laboratory Medicine, Universityof California, San Francisco, discussed the increasing incidenceof anal intraepithelial neoplasia (AIN) among HIV-infected individuals.

Said Dr. Palefsky, "High-grade AIN is very common in HIVinfection and should be considered a precursor to anal cancer."He also noted that AIN may possibly be implicated in the potentiationof HIV transmission, especially among those who are the recipientsof anal sexual intercourse.

Dr. Palefsky told the panel that the incidence of anal cancerin men who have practiced anal intercourse is about the same asthe incidence of cervical cancer in women prior to the availabilityof Pap smear screening.

Would it not then be reasonable to think, Dr. Palefsky suggested,that aggressive treatment for AIN might prevent anal cancer, orat least significantly decrease its incidence?

Dr. Trimble also talked about the relationship of HIV infectionto cervical cancer. HIV infection can be transmitted sexually,and immunosuppressed women are at particularly high risk of neoplasiaof the lower genital tract.

He pointed out that HIV-positive women with preinvasive diseasehave higher grade lesions, with more frequent multisite involvement,and experience faster progression of lower genital tract neoplasiathan do HIV-negative women.

Philip Pizzo, chief, NCI Pediatric Oncology Branch, said thatthe overall risk for children with immunodeficiency disordersto develop cancer is 4%--330 times greater than the rate of cancerexpected in otherwise healthy children. Moreover, survivors ofchildhood cancer have a 10 to 20 times higher risk of other cancers;being HIV positive makes them even more vulnerable.

Most Common Pediatric Cancers

The most common cancers in HIV-infected children are Kaposi'ssarcoma, Burkitt's lymphoma, immunoblastic lymphoma, and primaryCNS lymphoma, Dr. Pizzo said.

The incidence of non-Hodgkin's lymphoma is 360 times greater inHIV-infected children than in those who are HIV negative, he said.Extranodal involvement occurs in 85% of HIV-positive children(GI tract, bone marrow, heart, kidneys, liver, bone, and brain),and primary CNS disease accounts for 4% to 40% of all non-Hodgkin'slymphoma.

Articles in this issue

Physicians Take Aim at Localized Prostate Cancer Treatment Controversy in 'Shootout'
CA 125 Predicts Response to Chemo in Ovarian Ca
Biochemical Modulation Promising in RT-Resistant GI Cancer
Cancer Institute of NJ Adds to its Staff
A Century of Breast Cancer Litigation Is 'Deconstructed'
New Depot Formulation of LHRH Analogue Allows 12-Week Dosing
NSABP Investigation Threatens Academic Freedom for All: Fisher
Cancer Fax Directory in 3rd Edition
HIV-Related Malignancies Increasing, Physicians Tell Panel
Breast Cancer Risk Factors Remain Elusive Target
Conference Celebrates 100 Years of Radiology
Coalition Promotes Worksite Cancer Screening
Search for Ovarian Cancer Screen Must Look Beyond Ultrasound
DNA Defects Predict Endometrial Ca Prognosis
Cost Studies Help Determine Best BMT Use

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
5 experts are featured in this series
4 experts in this video
2 experts are featured in this series.
4 experts in this video
4 experts in this video
4 experts in this video
2 experts are featured in this series.
Related Content

Experts analyze the evolving landscape of melanoma treatment, highlighting key clinical trials and strategies for optimizing patient outcomes.

Applying Clinical Trials to Patient Cases: The Melanoma Landscape

ONCOLOGY Staff
July 26th 2025
Article

Experts analyze the evolving landscape of melanoma treatment, highlighting key clinical trials and strategies for optimizing patient outcomes.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Results from the phase 3 GMMG-HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.

Isatuximab Combo Approved in the EU for Transplant-Eligible NDMM

Roman Fabbricatore
July 25th 2025
Article

Results from the phase 3 GMMG-HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.

Novel Oral KRAS G12D Inhibitor Receives FDA Fast Track Designation in Advanced PDAC

Tim Cortese
July 25th 2025
Article

Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.


Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

Russ Conroy
July 25th 2025
Article

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Related Content

Experts analyze the evolving landscape of melanoma treatment, highlighting key clinical trials and strategies for optimizing patient outcomes.

Applying Clinical Trials to Patient Cases: The Melanoma Landscape

ONCOLOGY Staff
July 26th 2025
Article

Experts analyze the evolving landscape of melanoma treatment, highlighting key clinical trials and strategies for optimizing patient outcomes.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Results from the phase 3 GMMG-HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.

Isatuximab Combo Approved in the EU for Transplant-Eligible NDMM

Roman Fabbricatore
July 25th 2025
Article

Results from the phase 3 GMMG-HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.

Novel Oral KRAS G12D Inhibitor Receives FDA Fast Track Designation in Advanced PDAC

Tim Cortese
July 25th 2025
Article

Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.


Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

Russ Conroy
July 25th 2025
Article

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.